Life sciences · Preprint
arXiv · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Preprint.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective: This study aims to determine whether a hip-exoskeleton policy trained in simulation, by co-adapting with a musculoskeletal human model under a metabolic-energy reward, reduces the metabolic cost of walking in new users without per-user tuning, and how mechanical-power shaping affects the learned assistance. Methods: We developed MARL-Exo, a multi-agent reinforcement learning framework in which a full-body human model (304 muscle actuators; randomized anatomy, gait, and speed) and a bilateral hip-exoskeleton policy are trained concurrently in two stages. The exoskeleton observes only delayed hip kinematics and its past commands; its reward includes muscle metabolic power from a physiologically based energetics model, alone (Metabolic) or with mechanical-power shaping (Metabolic + Power). The Metabolic policy was deployed and tested without retraining in eight healthy adults walking at 1.25 m/s, using indirect calorimetry. Results: In simulation, the Metabolic policy reduced modeled muscle metabolic power by 13.8% relative to no-device walking, versus 8.8% for Metabolic + Power. On hardware, MARL-Exo reduced net metabolic rate by 18.3 $\pm$ 6.6% relative to Passive in all eight participants. Relative to No-Exo, the mean reduction was 7.4 $\pm$ 10.0%; six participants more than offset the 13.1% device-wearing penalty, walking up to 24.2% below their No-Exo cost. Conclusion: A metabolically informed policy co-adapted in simulation transferred to users without per-user tuning and consistently reduced the metabolic cost of walking with the device, while explicit power shaping reduced the simulated benefit. Significance: Unlike per-user human-in-the-loop optimization, this approach yields a single population-level controller and allows assistance objectives to be screened in simulation before human testing.